Nurix Therapeutics
NRIX
163 hedge funds and large institutions have $1.01B invested in Nurix Therapeutics in 2025 Q2 according to their latest regulatory filings, with 23 funds opening new positions, 69 increasing their positions, 43 reducing their positions, and 30 closing their positions.
895% more call options, than puts
Call options by funds: $1.72M | Put options by funds: $173K
60% more repeat investments, than reductions
Existing positions increased: 69 | Existing positions reduced: 43
4.37% more ownership
Funds ownership: 111.48% → 115.85% (+4.4%)
0% more capital invested
Capital invested by funds: $1.01B → $1.01B (+$825K)
4% less funds holding
Funds holding: 170 → 163 (-7)
23% less first-time investments, than exits
New positions opened: 23 | Existing positions closed: 30
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
+$37.7M |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$9.9M |
| 3 |
VPC
Vestal Point Capital
New York
|
+$9.45M |
| 4 |
PA
Perceptive Advisors
New York
|
+$8.64M |
| 5 |
Morgan Stanley
New York
|
+$7.57M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
-$18.6M |
| 2 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$15.8M |
| 3 |
BlackRock
New York
|
-$12.7M |
| 4 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
-$8.51M |
| 5 |
SC
Samlyn Capital
New York
|
-$6.12M |
NRIX Hedge Fund Activity: Q2 2025 in Review
163 of the 7,596 institutional investors tracked by Wall St. Rank reported a position in Nurix Therapeutics (NRIX) for Q2 2025, worth a combined $1.01B — up 0.08% from $1.01B a quarter earlier.
Sellers outnumbered buyers: 30 funds closed out of NRIX and 23 opened new positions — a net loss of 7 holders — while 43 trimmed existing stakes and 69 added.
The largest buyer was Point72 Asset Management, adding an estimated $37.7M. The largest seller was Wellington Management Group, cutting an estimated $18.6M.
- 163 institutional investors held Nurix Therapeutics (NRIX) as of Q2 2025, down from 170 in Q1 2025.
- Funds reported $1.01B of Nurix Therapeutics stock for Q2 2025, up 0.08% quarter-over-quarter.
- 23 funds opened new Nurix Therapeutics positions in Q2 2025 and 30 closed out, a net change of -7 holders.
- The largest Nurix Therapeutics buyer in Q2 2025 was Point72 Asset Management, an estimated $37.7M added.
- The largest Nurix Therapeutics seller in Q2 2025 was Wellington Management Group, an estimated $18.6M sold.
Based on aggregated 13F filings for Q2 2025.